1 Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide. IARC CancerBase No 11, 2013. http://globocan.iarc.fr.
2 Lowe KA, Chia VM, Taylor A, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 2013;130:107-14.
3 Cancer Research UK. 2014. www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/incidence/uk-ovarian-cancer-incidence-statistics.
4 Cancer Research UK. 2013. www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/incidence/uk-ovarian-cancer-incidence-statistics.
5 Maringe C, Walters S, Butler J, et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol2012;127:75-82.
6 Sundar S. Benign and malignant ovarian masses. In: Obstetrics and gynaecology: an evidence-based text for MRCOG. 2010, Hodder.
7 Perets R, Wyant GA, Muto KW, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013;24:751-65.
8 Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia? Lancet 1971;2:163.
9 Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012;30:2654-63.
10 Royal College of Obstetricians and Gynaecologists. Management of women with a genetic predisposition to gynaecological cancers. Scientific Impact paper No 48, Feb 2015.
11 Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst 2015;107:379.
12 Manchanda R, Legood R, Burnell M, et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J Natl Cancer Inst 2015;107:380.
13 Candido-dos-Reis FJ, Song H, Goode EL, et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res 2015;21:652-7.
14 Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109:221-7.
15 Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 2009;339:b2998.
16 Wheatley G. Ovarian cancer. Usefulness of abdominal symptoms in early diagnosis. BMJ 2009;339:b3954.
17 Pitts MK, Heywood W, Ryall R, et al. High prevalence of symptoms associated with ovarian cancer among Australian women. Aust N Z J Obstet Gynaecol 2011;51:71-8.
18 Lim AW, Mesher D, Sasieni P. Estimating the workload associated with symptoms-based ovarian cancer screening in primary care: an audit of electronic medical records. BMC Fam Pract 2014;15:200.
19 Sharma A, Menon U, Jacobs IJ. Symptoms in the diagnosis of ovarian cancer. In: The yearbook of obstetrics and gynaecology. T Hillard, ed. 2007, 159-70.
20 Lyratzopoulos, G., et al., Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience survey in England. Lancet Oncol 2012;13:353-65.
21 Lyratzopoulos G, Neal RD, Barbiere JM, Rubin GP, Abel GA. The relative length of the patient and the primary care interval in patients with 28 common and rarer cancers. Br J Cancer 2015;112(Suppl 1):S35-40.
22 Lyratzopoulos G, Wardle J, Rubin G. Rethinking diagnostic delay in cancer: how difficult is the diagnosis? BMJ 2014;349:g7400.
23 Elliss-Brookes L, McPhail S, Ives A, et al. Routes to diagnosis for cancer—determining the patient journey using multiple routine data sets. Br J Cancer 2012;107:1220-6.
24 Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 2015;112(Suppl 1):S92-107.
25 National Comprehensive Cancer Network. 2015. www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
26 National Institute for Health and Care Excellence, The recognition and initial management of ovarian cancer. (Clinical guideline 122.) 2011.http://guidance.nice.org.uk/CG122.
27 Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol 2012;13:285-91.
28 Andersen MR, Lowe KA, Goff BA. Value of symptom-triggered diagnostic evaluation for ovarian cancer. Obstet Gynecol 2014;123:73-9.
29 Moss EL, Moran A, Reynolds TM, Stokes-Lampard H. Views of general practitioners on the role of CA125 in primary care to diagnose ovarian cancer. BMC Womens Health 2013;13:8.
30 Rai N, Nevin J, Downey G, et al. Outcomes following implementation of symptom triggered diagnostic testing for ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2015;187:64-9.
31 Valentin L, Ameye L, Franchi D, et al. Risk of malignancy in unilocular cysts: a study of 1148 adnexal masses classified as unilocular cysts at transvaginal ultrasound and review of the literature. Ultrasound Obstet Gynecol 2013;41:80-9.
32 Sharma A, Gentry-Maharaj A, Burnell M, et al. Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study. BJOG 2012;119:207-19.
33 Timmerman D, Ameye L, Fischerova D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ 2010;341:c6839.
34 Royal College of Obstetricians and Gynaecologists/British Society for Gynaecological Endoscopy. Green top guideline No 62. Management of suspected ovarian masses in premenopausal women. Nov 2011, RCOG.
35 Menon U, Ryan A, Kalsi J, et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol 2015;33:2062-71.
36 McAlpine JN, Hanley GE, Woo MM, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014;210:471 e1-11.
37 Manchanda R, Burnell M, Abdelraheim A, et al. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. BJOG 2012;119:527-36.
38 Rosenthal AN. Ovarian cancer screening in the high-risk population—the UK Familial Ovarian Cancer Screening Study (UKFOCSS). Int J Gynecol Cancer 2012;22(Suppl 1):S27-8.
39 Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68.
40 Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013;5:167ra4.
41 Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25.
Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.